id: naltrexone_treatment_to_aud_treatment_response
name: Naltrexone Treatment for AUD â†’ Alcohol Use Disorder Treatment Response
from_node:
  node_id: naltrexone_treatment
  node_name: Naltrexone Treatment for AUD
to_node:
  node_id: aud_treatment_response
  node_name: Alcohol Use Disorder Treatment Response
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Naltrexone is administered as pharmacotherapy for alcohol use disorder
  management'
- 'Step 2: Reward-driven drinkers show differential neurobiological response to opioid
  antagonism'
- 'Step 3: Naltrexone blocks opioid receptors, reducing rewarding effects of alcohol
  consumption'
- 'Step 4: This leads to improved treatment outcomes in specific patient subgroups'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Laura B Ferguson et al. 2022. "RNA biomarkers for alcohol use
    disorder.." *Frontiers in molecular neuroscience*. https://doi.org/10.3389/fnmol.2022.1032362
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.672407'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: reward_drinking_phenotype
  direction: strengthens
  strength: moderate
  description: Reward-drinkers show better response to naltrexone compared to acamprosate,
    suggesting drinking motivation phenotype moderates treatment efficacy
